Latest Life Science News / Updates 👇 📌 TORL BioTherapeutics, LLC is the latest biotech to benefit from the ADC boom, bringing in $158 million in a B2 financing round. ➡ Asher Biotherapeutics has closed a $55 million series C to support the mission of developing therapies for cancer, autoimmune and infectious diseases. ◾ Canaan Partners adds $100m for Biotech investments plus brings in Uwe Schoenbeck to the team from Pfizer. 📌 Pathios Therapeutics drew in $25 million for the first close of a Series B raise that should help the UK biotech test its first-in-class solid tumor candidate in clinical trials by the end of the year. ◾ Alvotech and Teva Pharmaceuticals have announced approval from the FDA for Selarsdi via subcutaneous injection. ➡ Scopio Labs receives groundbreaking FDA Clearance for first-ever Digital Bone Marrow Aspirate application 📌 Stoke Therapeutics appoints Jason Hoitt as Chief Commercial Officer ◾ Sensorium Therapeutics appoints Sam Rasty as Chief Business Officer
Graham Sanders’ Post
More Relevant Posts
-
This Week in #Biotech & #Pharma: Innovation, Partnerships, and Big Moves 🚀 Biotech Breakthroughs • Sibylla Biotech and MD Anderson Cancer Center are tackling #cancer with cutting-edge folding-interfering degraders—reshaping how we think about protein targets. • Rgenta Therapeutics Inc. and GSK dive deeper into #RNA-targeting #smallmolecules for #oncology, pushing the boundaries of what’s possible. 💡 Pharma Innovations • Gilead Sciences partners with Genesis Therapeutics to combine #AI and small molecules for novel therapies—exciting times for #precisionmedicine! • Sanofi teams up with Belharra Therapeutics to revolutionize immunological disease treatments with state-of-the-art discovery tech. 📉 Industry Shake-Ups • Alnylam Pharmaceuticals wins FDA approval for a hypertension #RNAi therapy—first of its kind! • On a somber note, Amgen announces significant #layoffs as part of strategic cost management. What excites you most about this week’s progress?
To view or add a comment, sign in
-
It’s been March Madness in the biotech industry this month with 8 VC rounds north of $130M. Here they are 👇 Mirador Therapeutics Precision medicine for immune-mediated inflammatory and fibrotic diseases Amount Raised: $400 million (Series A) Alumis Oral therapies to combat immune-mediated diseases Amount Raised: $259 million (Series C) Capstan Therapeutics Ttargeted in vivo RNA-based therapies Amount Raised: $175 million (Series B) Sionna Therapeutics Small molecule therapies for cystic fibrosis (CF) Amount Raised: $182 million (Series C) Clasp Therapeutics Innovating T-cell engagers for immuno-oncology. Amount Raised: $150 million (Series A) Engrail Therapeutics Transformational therapies to patients with devastating disorders of the nervous system Amount Raised: $157 million (Series B) FogPharma Drugs to address the limitations of today’s precision medicines and achieve universal druggability. Amount Raised: $145 million (Series E) Tubulis GmbH Uniquely matched antibody-drug conjugates (ADCs) Amount Raised: $138.8 million (Series B2) Credit: Fierce Biotech fundraising tracker
To view or add a comment, sign in
-
Latest Life Science News / Updates : 📌 Regeneron is committing up to $500 million over the next five years for its new private financing arm. 📌 Clario has purchased ArtiQ, an artificial intelligence software developer that creates AI solutions for diagnosing and treating patients with respiratory disease. 📌 Genmab announces acquisition of ProfoundBio for $1.8 billion 📌 Obsidian Therapeutics has raised $160 million in a series C. 📌 Alterome Therapeutics, Inc Therapeutics has closed a $132 million series B, cash that will go toward the development of next-gen, small molecule targeted oncology therapies. 📌 Diagonal Therapeutics has raised $128 million to advance its antibody agonist-building platform. 📌 Boundless Bio is bringing in $100 million from its IPO as the precision oncology company becomes the latest biotech to go public in 2024. 📌 Lonza have appointed new CEO - Wolfgang Wienand
To view or add a comment, sign in
-
️ 🗞️ In The News CEO & MD Dr Chris Burns’ accomplishment as co-recipient of the 2024 Prime Minister’s Prize for Innovation has been featured in Stockhead this week. The article by journalist Nadine McGrath, outlines the path taken by Dr Burns and scientific collaborator Professor Andrew Wilks through the development of momelotinib - a drug to help treat myelofibrosis - and how Dr Burns is now applying his expertise to Amplia's research into narmafotinib, and its potential in pancreatic cancer trials. Here’s an excerpt: “𝘛𝘩𝘦 𝘈𝘊𝘊𝘌𝘕𝘛 𝘵𝘳𝘪𝘢𝘭 𝘪𝘴 𝘦𝘹𝘱𝘭𝘰𝘳𝘪𝘯𝘨 𝘵𝘩𝘦 𝘢𝘤𝘵𝘪𝘷𝘪𝘵𝘺 𝘰𝘧 𝘈𝘛𝘟’𝘴 𝘯𝘢𝘳𝘮𝘢𝘧𝘰𝘵𝘪𝘯𝘪𝘣 (𝘈𝘔𝘗945), 𝘪𝘯 𝘤𝘰𝘮𝘣𝘪𝘯𝘢𝘵𝘪𝘰𝘯 𝘸𝘪𝘵𝘩 𝘴𝘵𝘢𝘯𝘥𝘢𝘳𝘥-𝘰𝘧-𝘤𝘢𝘳𝘦 𝘤𝘩𝘦𝘮𝘰𝘵𝘩𝘦𝘳𝘢𝘱𝘺, 𝘪𝘯 𝘢𝘥𝘷𝘢𝘯𝘤𝘦𝘥 𝘱𝘢𝘯𝘤𝘳𝘦𝘢𝘵𝘪𝘤 𝘤𝘢𝘯𝘤𝘦𝘳 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴. 𝘕𝘢𝘳𝘮𝘢𝘧𝘰𝘵𝘪𝘯𝘪𝘣 𝘪𝘴 𝘈𝘛𝘟’𝘴 𝘣𝘦𝘴𝘵-𝘪𝘯-𝘤𝘭𝘢𝘴𝘴 𝘪𝘯𝘩𝘪𝘣𝘪𝘵𝘰𝘳 𝘰𝘧 𝘵𝘩𝘦 𝘱𝘳𝘰𝘵𝘦𝘪𝘯 𝘍𝘈𝘒, 𝘢 𝘱𝘳𝘰𝘵𝘦𝘪𝘯 𝘰𝘷𝘦𝘳-𝘦𝘹𝘱𝘳𝘦𝘴𝘴𝘦𝘥 𝘪𝘯 𝘱𝘢𝘯𝘤𝘳𝘦𝘢𝘵𝘪𝘤 𝘢𝘯𝘥 𝘰𝘵𝘩𝘦𝘳 𝘤𝘢𝘯𝘤𝘦𝘳𝘴. 𝘐𝘵 𝘩𝘢𝘴 𝘣𝘦𝘦𝘯 𝘨𝘳𝘢𝘯𝘵𝘦𝘥 𝘧𝘢𝘴𝘵 𝘵𝘳𝘢𝘤𝘬 𝘥𝘦𝘴𝘪𝘨𝘯𝘢𝘵𝘪𝘰𝘯 𝘣𝘺 𝘵𝘩𝘦 𝘍𝘋𝘈, 𝘸𝘩𝘪𝘤𝘩 𝘪𝘴 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘵𝘰 𝘥𝘳𝘶𝘨𝘴 𝘵𝘩𝘢𝘵 𝘮𝘢𝘺 𝘱𝘳𝘰𝘷𝘪𝘥𝘦 𝘢𝘯 𝘢𝘥𝘷𝘢𝘯𝘵𝘢𝘨𝘦 𝘰𝘷𝘦𝘳 𝘤𝘶𝘳𝘳𝘦𝘯𝘵 𝘵𝘩𝘦𝘳𝘢𝘱𝘪𝘦𝘴 𝘪𝘯 𝘵𝘩𝘦 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵 𝘰𝘧 𝘴𝘦𝘳𝘪𝘰𝘶𝘴 𝘤𝘰𝘯𝘥𝘪𝘵𝘪𝘰𝘯𝘴.” Take a look 👉 https://lnkd.in/gA8WSGiQ $ATX #Amplia #biotech #pharma #innovation #pancreaticcancer #clinicaltrials
To view or add a comment, sign in
-
Precision Cancer Therapies Market: Growth Drivers and Leading Players Download Sample URL: https://lnkd.in/dZdPuCSi The precision cancer therapies market is expanding rapidly, driven by advancements in genomics, personalized medicine, and targeted therapies. The increasing demand for effective cancer treatments, combined with the rise of biomarker-based therapies and improved diagnostic tools, is propelling market growth. Personalized therapies offer more effective, tailored treatment options, enhancing patient outcomes and driving the global market forward. Top Key Players: Novartis, Roche, Pfizer, Merck Group, AstraZeneca, AbbVie, Amgen, Genentech, Sanofi, Regeneron, Bayer, Vertex Pharmaceuticals, Blueprint Medicines, Horizon Therapeutics, Biogen, Merck KGaA, Darmstadt, Germany, Exelixis, SEATTLE GENETICS UK, LIMITED, Stemline Therapeutics, Foundation Medicine, Illumina, Cigna Healthcare, BioCryst Pharmaceuticals, Inc., Clovis Oncology, Hikma Pharmaceuticals, Boehringer Ingelheim, Medivation. #PrecisionCancerTherapies #CancerTreatment #PersonalizedMedicine #TargetedTherapy #Biomarkers
To view or add a comment, sign in
-
Encourage people to attend the inaugural SITC Immuno-Oncology Drug Development Summit September 30-October 1, 2024 in Boston, MA. Co-organized by Amy McKee, Pedro Romero, Luisa Salter-Cid, Alexandra Snyder, Jon Wigginton. We now have over 25 IO drugs that have been approved, and this number will only continue to grow as science accelerates. From this experience, we as a field have learned that there are important distinctions in developing IO agents compared to conventional modalities such as targeted and cytotoxic therapeutics. There has been a significant need for some time for a program like this, to reflect on our learnings to date and discuss/debate the future. This program will include key stakeholders from the academic, pharma/biotech, regulatory and financial sectors, and is intended to promote dialogue between these key contributors to IO drug development as we all work together to make things better for patients. Terrific support from SITC leadership, including Leisha Emens (President), James Gulley (Vice-President), SITC board, SITC biotech committee led by Kristen Hege and Zhen Su, and of course SITC staff team led by Mary Dean. #cancer #oncology #immunooncology #cancerimmunotherapy #immunotherapy #drugdevelopment #bispecific #cytokine #celltherapy
To view or add a comment, sign in
-
🤝 Generate:Biomedicines & Novartis collaboration A new, massive, #AI-based drug discovery deal was announced on September 24. Novartis and Generate:Biomedicines announced a multi-target collaboration to discover and develop protein therapeutics. The deal leverages “The Generate Platform”, a proprietary genAI platform and combines it with Novartis capabilities to accelerate drug discovery and development. The scope of targets or therapeutic areas is not disclosed. However, as per the terms of the collaboration, Generate:Biomedicines will receive a total upfront payment of $65m. Total performance-based milestones are evaluated above $1Bn along with low double-digits royalties. As of today, the AI-powered biotech has built a pipeline of more than 15 candidates in immunology, oncology, ADCs and infectious diseases with partners like Amgen, MD Anderson Cancer Center and Roswell Park Comprehensive Cancer Center. 🔭 On a larger trend, AI in early-stage drug development is here to stay, with drug development costs ranging from $2.8Bn to $6.1Bn per approval, quoting Andrii Buvailo, Ph.D. and Alex Zhavoronkov. 📌 As always, check out sources in first comment! #artificialintelligence #machinelearning #drugdiscovery
To view or add a comment, sign in
-
Only a few days left to register for the 9th CAR-TCR Summit at the best rate! In case you haven't seen it yet, full agenda here: https://ter.li/eugziv This remains the industry's favorite meeting for CAR-T and TCR-based drug development, where you'll hear brand new insights from key academics, innovative biotechs and big-player pharma. We asked the industry what hot topics should be up for discussion this year - and you have spoken! So, in 2024, you'll join conversations on: 💢 Autoimmune applications of cell therapy, with advice from Cabaletta Bio & Adicet Bio, Inc 💢 How to innovate and accelerate your manufacturing processes with first-hand learnings from Gracell Biotechnologies, Kyverna Therapeutics, Takeda, Bristol Myers Squibb & Verismo Therapeutics 💢 How to improve efficacy in solid tumors with insights from Affini-T Therapeutics, Inceptor Bio, Obsidian Therapeutics & Memorial Sloan Kettering Cancer Center 💢 Advice and insights from investors including Vida Ventures, LLC, Sofinnova Partners & Northpond Ventures, plus how to secure cash runways with experienced players like Daiichi Sankyo US, Bristol Myers Squibb & Takeda Full details in the agenda here: https://ter.li/eugziv This is also your biggest networking opportunity of the year as 1,000+ cell therapy experts come together to collaborate, build professional networks and socialize with new and old friends. Don't be the only one to miss it! Best value tickets are available now. Access your saving here: https://ter.li/d87kfc Isabella Maxton Jade Wallace Elly Kanaan Kiran Thomson Luke O'Neill Molly Jones Molly Biggin Rebecca Legge Sadhbh Ni Chiobhain
To view or add a comment, sign in
-
#Smallmolecules represent the next frontier of immuno-oncology and such drugs now entering the clinical research stage. #Kumquat has been on the forefront with its first small-molecule #immunooncology partnership with #EliLilly in July 2021. Takeda's #oncologypipeline consists primarily of small molecules which means that there are several combination opportunities that could be explored with Kumquat`s molecule. Between Takeda and Eli Lilly, Kumquat stands to make ~$3.2B in future development, regulatory and commercial milestones. #innovation #oncology
#Takeda's exclusive partnership with biotech company #KumquatBiosciences could result in over $1.2 billion in future milestone payments for Kumquat's unnamed small-molecule immuno-oncology inhibitor. After phase 1 trials, Takeda can secure global licensing rights and manage further development and commercialization. Kumquat stands to receive up to $130 million in initial payments and tiered royalties. This collaboration supports Takeda’s focus on driving innovative treatments to address unmet needs in #cancercare. #biotech #pharma #oncology #collaboration #innovation #immunooncology Takeda Takeda Oncology Kumquat Biosciences Inc. Detailed News: https://lnkd.in/dMSzuGmm Follow our page for more industry updates: https://lnkd.in/de5zNWmK
Takeda inks sweet $1.2B-plus deal with Kumquat for immuno-oncology program
fiercebiotech.com
To view or add a comment, sign in
-
#Takeda's exclusive partnership with biotech company #KumquatBiosciences could result in over $1.2 billion in future milestone payments for Kumquat's unnamed small-molecule immuno-oncology inhibitor. After phase 1 trials, Takeda can secure global licensing rights and manage further development and commercialization. Kumquat stands to receive up to $130 million in initial payments and tiered royalties. This collaboration supports Takeda’s focus on driving innovative treatments to address unmet needs in #cancercare. #biotech #pharma #oncology #collaboration #innovation #immunooncology Takeda Takeda Oncology Kumquat Biosciences Inc. Detailed News: https://lnkd.in/dMSzuGmm Follow our page for more industry updates: https://lnkd.in/de5zNWmK
Takeda inks sweet $1.2B-plus deal with Kumquat for immuno-oncology program
fiercebiotech.com
To view or add a comment, sign in